The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Alberto Hernando-Calvo
Travel, Accommodations, Expenses - Kyowa Kirin International; Merck Serono
 
Richard D. Carvajal
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aura Biosciences; Bristol-Myers Squibb/Medarex (Inst); Castle Biosciences; Chimeron Bio; Corvus Pharmaceuticals (Inst); Genzyme; Genzyme; IDEAYA Biosciences (Inst); Immunocore; InxMed; Iovance Biotherapeutics; Merck; Mirati Therapeutics (Inst); Novartis (Inst); Oncosec; Pfizer (Inst); Pierre Fabre; Plexxikon (Inst); PureTech; Regeneron; Regeneron; Rgenix; Roche/Genentech (Inst); Roche/Genentech (Inst); Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Van K. Morris
Consulting or Advisory Role - Axiom Healthcare Strategies; Bicara Therapeutics; BioMedical Insights; Boehringer Ingelheim; Incyte; SERVIER
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Immatics; Pfizer (Inst)
 
Paul K. Paik
Honoraria - Bicara Therapeutics; EMD Serono; Mirati Therapeutics; Takeda; Xencor
Consulting or Advisory Role - Bicara Therapeutics; Calithera Biosciences; EMD Serono; Mirati Therapeutics; Takeda; Xencor
Research Funding - Bicara Therapeutics; Boehringer Ingelheim; EMD Serono
 
Dan Paul Zandberg
Consulting or Advisory Role - Blueprint Medicines; Macrogenics
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
John M. Kaczmar
Honoraria - Triangle Insights Group
Consulting or Advisory Role - Bicara Therapeutics; Coherus Biosciences; Rakuten Medical
 
Liviu Niculescu
Employment - Bicara Therapeutics; Bluebird Bio; Vertex (I)
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics; Pfizer
 
David Bohr
Stock and Other Ownership Interests - Gilead Sciences; Johnson & Johnson
 
Ralf Reiners
Employment - Bicara Therapeutics; Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Bicara Therapeutics
 
Elham Gharakhani
Employment - Bicara Therapeutics; Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Bicara Therapeutics; Biogen
 
Rachel Salazar
Employment - Bicara Therapeutics
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics
Travel, Accommodations, Expenses - Bicara Therapeutics
 
Sanela Bilic
No Relationships to Disclose
 
Glenn J. Hanna
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP